Dublin, Jan. 26, 2016 -- Research and Markets (http://www.researchandmarkets.com/research/9bkcr3/injectable_drug) has announced the addition of the "Injectable Drug Delivery Devices, Markets, Forecasts" report to their offering.
This report examines the key therapeutic, product, market and regulatory factors for injectable drugs across ten major disease and therapeutic classes, providing essential insight and forecasts into the implications of this evolving landscape.
The past decade has seen a dramatic shift in terms of the types of approved injectable drugs, the diseases they target, and the devices used to deliver them. This shift has fostered change on several levels of the healthcare sector. The injectable drug segment has seen a marked increase in the level of drug/device integration, as prefilled syringes and specialized injection devices proliferate in response to safety and economic challenges posed by recombinant protein drugs, while administration of injectables has moved increasingly from practitioner offices and healthcare facilities to patient homes.
What You Will Learn
- What injectable drugs are currently marketed, how are they administered, what are the device specifics, and who markets them?
- What are the injection device types that are driving the market? What is their market share and who are the leading suppliers?
- What new injection device classes have recently been launched and was is their probable impact going to be on the injectables sector?
- What does the injectable drugs supply chain consist of, who are the key suppliers, their manufacturing infrastructure and locations, their capabilities?
- What are the major factors driving injectable drug demand?
- How important are drug developer-device manufacturer relationships and what are the key alliances in the industry?
- What is the size & breakdown of the injectable drug market today? What will it look like in 2022?
Key Topics Covered:
1. Executive Summary
2. Injectable Drug Market Dynamics
- The Injectable Drug Ecosystem
- Injectable Drug Demand Drivers
- Drug Development Factors
- Market Factors
- Technology Factors
- Competitive Landscape
- Risks and Opportunities
3. Injectable Drug-Device Selection Criteria
- Stability and Material Selection Issues
- Single vs Multi-Dose Devices
- Lyophilized Drugs/Reconstitution
- Syringe Safety/Sharps Protection
- Needle Configuration Strategies
- Disposable Drug Cartridges
- Human Engineering/Ergonomics
- Branding/Private Labeling
4. Injectable Drug Delivery - Device Segments
- Autoinjectors
- Autoinjector-specific Selection Factors
- Autoinjector Device Categories
- Drugs and Therapeutic Segments
- Needle-free Injectors
- Device Categories
- Needle-free Injector-specific Selection Factor Pen Injectors
- Pen Injector Device Categories
- Branded Drug/Pen Injector Product by Segment
- Prefilled Syringe Device Categories
- Glass Prefilled Syringes
- Plastic Prefilled Syringes
- Safety Syringes
- Prefillable Integrated Safety Syringes
- Non-Prefillable Integrated Safety Syringes
- Wearable Injectors
- Patch Injectors
- Subcutaneous Infusion Devices
5. Injectable Drug Delivery - Therapeutic Segment
- Analysis & Forecasts
- Anaphylaxis
- Anticoagulants
- Antivirals
- Autoimmune Diseases
- Emergency Medicine
- Hematopoietics
- Hormone Replacement
- Metabolic Diseases
- Neurology
- Reproductive Health
- Vaccines
6. Injectable Drug Therapeutics - Market Factors
- Regulatory Factors and Issues
- Sharps Legislations
- Managed Care & Healthcare Economics
7. Company Profiles
For more information visit http://www.researchandmarkets.com/research/9bkcr3/injectable_drug
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716


American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Anta Sports Expands Global Footprint With Strategic Puma Stake
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Washington Post Publisher Will Lewis Steps Down After Layoffs 



